Caplacizumab
| Monoclonal antibody | |
|---|---|
| Type | Single domain antibody |
| Source | Humanized |
| Target | VWF |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 915810-67-2 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C1213H1891N357O380S10 |
| Molar mass | 27.88 kg/mol |
Caplacizumab (INN) is a bivalent VHH designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[1][2]
This drug is developed by Ablynx NV, and is currently in a phase III clinical trial.[3]
It is an anti-von Willebrand factor humanized immunoglobulin.[4] It acts by blocking platelet aggregation to reduce organ injury due to ischemia.[4] Results of the phase II TITAN trial have been reported.[4]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
- ↑ A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)
- 1 2 3 Immune Drug Tackles Microvascular Thrombosis Disorder. Feb 2016
This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.